Marco's Morning Report — Friday, July 3, 2026

Section A — Top Stories

Two that actually touch your floor.

SHM Converge 2026 "Updates in Hospital Medicine" — three that change how you round

The annual practice-changing-literature session out of Converge dropped a few gems worth internalizing. Metformin in the hospital: huge facility-level variation in whether it's continued, and patients whose metformin was kept on had lower 90-day hypoglycemia, lower 90-day mortality, and fewer readmissions — a nudge against the reflex hold. Calcium: stop correcting total calcium for albumin — the correction formula matched ionized only 63% of the time vs. 74% for plain total calcium; just order the ionized. SIADH: urea is an effective, underused fix — a meta-analysis had it raising serum sodium ~9.1 mEq/L.

Why it matters to you: all three land squarely on your elderly admits — the diabetic you're tempted to hold metformin on "just because," the hyponatremic SIADH you're fluid-restricting into a corner, and the daily albumin-corrected calcium that may be sending you chasing ghosts.

Talking point / action: worth a five-minute share at the next group meeting, and a candidate for your admission order-set and med-rec defaults review.

Update — Mets are sellers, and the fire sale is taking shape

New York sits ~36-51, about 10 games out of the last Wild Card, and the front office has committed to selling before the Aug. 3 deadline. Freddy Peralta is the name most likely to move (disappointing 5-7, 4.81 ERA over 18 starts), Clay Holmes is ramping back from a fractured fibula and could become another chip, and Luke Weaver is in the mix. This follows the earlier David Peterson-to-Cubs deal and the Mendoza firing.

Why it matters: a $365M payroll waving the white flag by early July is the story of the season for you and the family — the next month is about who's left standing, not the standings.

Follow: watch the Peralta market over the next four weeks — his return is the deadline's tell for how aggressively Stearns sells.

Section B — The Debate

Should doctors be exempt from Trump's $100,000 H-1B visa fee?

Why it's live: a Massachusetts federal court vacated the $100K fee on June 8, the administration is appealing, and SHM pressed HHS again on July 2 over the stalled J-1 waiver backlog stranding foreign-trained physicians bound for underserved areas. A bipartisan Physicians & Healthcare Workforce Act to carve out health workers is pending.

For an exemption

International medical graduates are roughly one in four practicing U.S. physicians, and rural counties are more than three times as dependent on them — so a $100,000-per-petition wall (up from ~$3,500) doesn't protect American patients, it closes oncology and OB service lines in places that can least backfill them. The AMA and AHA — with Rep. Mike Lawler's bipartisan bill — argue a targeted health-worker carve-out is the fix; over 70% of surveyed hospitals expect the fee to hit patient care directly. As one Hill op-ed put it, America trains these doctors, then forces them to leave.

Against a carve-out

Keep the fee applied across the board: special-interest exemptions are exactly how the H-1B program gets gamed, and a physician carve-out rewards employers who lean on imported labor instead of paying market wages or training domestic grads. The Center for Immigration Studies (Siddiqui) frames the court's rejection of the fee as safeguarding corporate fraud, not the rule of law, and CIS researchers (Camarota & Richwine) argue wage data show no genuine STEM shortage. The real answer, this side says, is lifting the Medicare residency (GME) caps so the U.S. trains more of its own physicians — not a permanent import subsidy.

Where it might land: the appeal of the June 8 ruling and the pending carve-out bill are the two forks to watch this summer.

Section C — On My Radar

Noteworthy, not urgent.

Sepsis: the 2026 SCCM/ESICM Surviving Sepsis update (129 recommendations) is circulating — worth a full read when you have a quiet night. Highlights.

Workforce: SHM's July 2 letter to HHS on the J-1 waiver backlog + $100K H-1B fee is the news event behind today's debate. Context.

Movies/TV worth queuing: critics are high on Cape Fear (Javier Bardem), Tina Fey's The Four Seasons, and The Miniature Wife; the Paul McCartney doc Man on the Run is landing well; The Pitt S2 still strong. RT roundup.

Golf tech: nothing brand-new past 48h — the sub-$250 Shot Scope LM1 radar unit (with a no-ball speed-training mode) and the Garmin Approach G82's new putting metrics remain the value stories.

Puerto Rico: DOE renewed PREPA emergency generation orders for the 2026 hurricane season; the Energy Bureau trimmed the utilities' requested base-rate revenue from ~$3.14B to $1.78B (a 43% cut). DOE.

Cuba (mainstream): no major new development past 48h — blackouts and scattered protests continue amid the U.S. oil-shipping blockade while Havana rolls out its 176-measure free-market reform package. Background.

Iran: the U.S. and Iran held separate Doha meetings July 1 and agreed to keep talking; the mid-June ceasefire holds but stays fragile over Israel–Hezbollah fighting in Lebanon. PBS.

Section D — Trends to Watch

The reflex-hold is under review. The metformin-continuation data joins a broader "don't automatically stop home meds on admission" current — expect more scrutiny of blanket inpatient holds on chronic meds in stable elderly patients.

Physician-workforce policy is moving from the courts to Congress. With the $100K fee vacated and appealed, the fight shifts toward statutory carve-outs and, increasingly, the long-frozen Medicare GME residency caps.

Launch-monitor price compression. Doppler-radar units are dipping under $250 with built-in speed training — practice data that used to cost a driver's worth is going mainstream.

Section E — Ideas & Opportunities

Bring the metformin-continuation and albumin-corrected-calcium findings to your next group/QI huddle — both are low-effort order-set tweaks with real elderly-inpatient upside.

Night off: Cape Fear (Bardem) if you want tension, Man on the Run if you want the McCartney story.

Keep an eye on the Peralta trade market as the Aug. 3 deadline tell.